JCO Acceptance Rate
JCO does not publish a strong official acceptance rate. The better submission question is whether the study delivers clinical oncology evidence that could change ASCO guidelines or oncology practice.
Senior Researcher, Oncology & Cell Biology
Author context
Specializes in manuscript preparation and peer review strategy for oncology and cell biology, with deep experience evaluating submissions to Nature Medicine, JCO, Cancer Cell, and Cell-family journals.
Journal evaluation
Want the full journal picture?
See scope, selectivity, submission context, and what editors actually want before you decide whether the journal is realistic.
Quick answer: there is no strong official JCO acceptance-rate number you should treat as exact. Third-party estimates place it in the 10–15% range. With a 2025 JCR impact factor of ~41.9, JCO is the highest-impact clinical oncology journal in the world and the ASCO flagship — the editorial bar is about practice-changing evidence, not just well-designed studies.
If the paper is a single-arm pilot or a small biomarker study without practice implications, the acceptance-rate discussion is mostly noise. The practice-changing evidence is the real issue.
What you can say honestly about the acceptance rate
ASCO does not publish a stable official acceptance rate for JCO. Third-party aggregators report estimates in the 10–15% range. Those are directionally useful — this is the most selective clinical oncology journal in the world — but the exact figure varies by source and year.
What is stable is the editorial posture:
- JCO is the ASCO flagship and the primary publication venue for landmark oncology trials
- the journal publishes the clinical evidence that oncologists worldwide use to guide treatment decisions
- randomized phase III trials, practice-changing phase II results, and large registry analyses are prioritized
- companion journals (JCO Oncology Practice, JCO Global Oncology, JCO Precision Oncology) absorb work below the flagship bar
That practice-changing standard is the real filter. Studies that are well-designed but incremental face very steep odds.
What the journal is really screening for
At triage, the editor is usually asking:
- does this study change how oncologists will treat patients?
- is the trial design definitive — randomized, adequately powered, with clinically meaningful endpoints?
- would ASCO present this at a plenary or clinical science symposium?
- does the evidence warrant updating clinical guidelines?
Papers that answer the first question — with a practice-changing result from a well-designed trial — survive triage at rates far above the baseline.
The better decision question
For JCO, the useful question is:
Is this study's evidence strong enough that ASCO guideline committees would consider it when updating treatment recommendations?
If yes, the journal is a strong fit. If the paper is a biomarker discovery, a translational finding, or a small clinical observation, the acceptance rate is not the constraint. The evidence level is.
Where authors usually get this wrong
The common misses are:
- centering strategy around an unofficial percentage instead of checking practice-changing potential
- submitting translational work that belongs in CCR or JCO Precision Oncology
- presenting underpowered trials or single-arm studies as definitive evidence
- underestimating the competition from landmark multicenter trials for the same slots
- ignoring the ASCO companion journals as realistic landing spots for strong work below the flagship bar
Those are evidence-level and scope problems before they are rate problems.
What to use instead of a guessed percentage
If you are deciding whether to submit, these pages are more useful than an unofficial rate:
- JCO cover letter
- JCO submission process
- JAMA Oncology acceptance rate (JAMA Network alternative)
- Lancet Oncology acceptance rate (Lancet portfolio)
- Annals of Oncology acceptance rate (ESMO flagship)
Together, they tell you whether the paper has enough clinical evidence, whether the editorial timeline is manageable, and whether a different oncology venue would be a cleaner fit.
Practical verdict
The honest answer to "what is the JCO acceptance rate?" is that ASCO does not publish one, and third-party estimates in the 10–15% range should be treated as approximate.
The useful answer is:
- yes, this is the most selective clinical oncology journal in the world
- no, a guessed percentage is not the right planning tool
- use practice-changing trial evidence, ASCO guideline relevance, and definitive study design as the real filter instead
If you want help pressure-testing whether this manuscript meets the JCO evidence bar before upload, a free Manusights scan is the best next step.
Sources
- 1. Journal of Clinical Oncology, ASCO.
- 2. JCO author center, ASCO.
- 3. Clarivate Journal Citation Reports, 2025 edition (IF ~41.9).
- 4. SCImago Journal & Country Rank: JCO, Q1 ranking.
Reference library
Use the core publishing datasets alongside this guide
This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: how selective journals are, how long review takes, and what the submission requirements look like across journals.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Dataset / benchmark
Biomedical Journal Acceptance Rates
A field-organized acceptance-rate guide that works as a neutral benchmark when authors are deciding how selective to target.
Reference table
Journal Submission Specs
A high-utility submission table covering word limits, figure caps, reference limits, and formatting expectations.
Before you upload
Want the full journal picture?
Scope, selectivity, what editors want, common rejection reasons, and submission context, all in one place.
These pages attract evaluation intent more than upload-ready intent.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Supporting reads
Conversion step
Want the full journal picture?
These pages attract evaluation intent more than upload-ready intent.